Moderna (MRNA) Price Target Lowered to $200 at Cowen, Analyst Cites Development Risks of Flu, RSV and CMV Programs
Tweet Send to a Friend
Cowen analyst Tyler Van Buren lowers his price target on Moderna (NASDAQ: MRNA) to $200 from $250, while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE